PHARMACEUTICAL IMPURITY STANDARD
NO.1 SUPPLIER & MANUFACTURER
Run for science and technology, promote human health
PHARMACEUTICAL IMPURITY STANDARD NO.1 SUPPLIER & MANUFACTURER
Run for science and technology, promote human health
Location: Home > NEWS & INSIGHTS

2024V16 | Challenge successful! EDQM admits structural error, QCS feedback is completely correct!

Time:2024-08-02


After 14 months, EP (EDQM) finally acknowledged that impurity J in the current version of the European Pharmacopoeia was structurally incorrect and determined that impurity J in the new edition of the Pharmacopoeia will be defined as an unknown structure.

 

 

Cause of the event


In May 2023, our center received feedback from a customer that the Flucloxacillin Sodium EP Impurity J provided by us did not match the relative retention time (RRT) specified in the standard: the RRT for impurity J included in the pharmacopoeia standard was 1.57, but the customer's actual RRT was 0.96. According to the European Pharmacopoeia EP11.0, the structural formula of impurity J is shown in Figure 1

 

图1.png 

Figure 1: EP Flucloxacillin impurity J screenshot and QCS official website structure

 

 

Product verification

 

 

After receiving feedback from after-sales service, our center attached great importance to and organized efforts to conduct a detailed review of the relevant data of impurity J, and finally confirmed that our impurity J is structurally consistent with impurity J in the European Pharmacopoeia (EP). Based on our center's product data and customer feedback, we suspect that the information included in the EP Impurity J Pharmacopoeia in the current version may be incorrect. In order to verify our own inference, in addition to reviewing the structural confirmation spectrum, our company specifically purchased EP's Flucloxacillin for peak identification CRSCAT: Y0002324) and conducted LC-MS data testing on the peak identification reference standard. After verification, no molecular weight signal related to EP impurity J (MW: 670.12) was detected after the main peak in the identification reference substance of EP's Flucloxacillin peak. The LC-MS data of the reference substance for the identification of Flucloxacillin peak are shown in Figure 2:

 

1.png2.png 

 

 

 

Figure 2: LC-MS data of EP Flucloxacillin peak identification reference substance

 

Based on the above test results and our product test data, we believe that the information included in the EP impurity J pharmacopoeia in the current version is indeed incorrect, the impurity J structure claimed in the current version of EP is not the component of the target peak with RRT of 1.5. Subsequently, our center shared the above information, as well as the structural identification data of impurity J and the testing data of CRS identification between impurity J and EP peaks, with the relevant personnel of EDQM (EP). At the same time, in October 2023, our center donated 20mg Flucloxacillin impurity J sample to EDQM for data validation, and the email content is shown in Figure 3 and Figure 4:

 

图3.png 

Figure 3: EP received feedback and replied to the email requesting a sample

 

图4.png 

Figure 4: EP provides sample receiving information

 

 

Conclusion

 

 

Recently, while our center communicated with EDQM that the peaks of impurities B and G in Amikacin EP were inconsistent with the pharmacopoeia standard chromatogram, we also received a formal response from EP regarding Flucloxacillin impurity J.The reply fully affirmed our work and clearly stated that the structural formula of impurity J in the current version of EP is incorrect. This error will be corrected in the new version of EP, where impurity J will be presented as an unknown structure. This content will be reflected in EP11.8 version, and the new version is expected to take effect in July 2025. See Figure 5 for details:

 

图5.png 

Figure 5: Reply from EP regarding Flucloxacillin impurity J and subsequent changes in various monograph

 

 

Summary

 

 

After 14 months, our center's data on the structure of Flucloxacillin EP impurity J was finally recognized by the European Pharmacopoeia Commission (EDQM) and acknowledged that the structure of Flucloxacillin EP impurity J was incorrect. EDQM has confirmed that the structural formula of impurity J will be removed from the 11.8 edition of the monograph.

 

Beyond topic

Scientific research is a serious matter that requires endurance, perseverance, and courage. We feel honored and gratified to be able to contribute to the development of the pharmaceutical industry. At the same time, we would like to express our gratitude to the customer for their continuous recognition and tolerance.


屏幕截图 2024-04-15 092448.jpg


Back

CONTACT US

Service hotline: +86 0755-66853366
Marketing Department: +86 136 7004 6396 (WeChat)
Email: sales@chem-strong.com
Office address: Room 1201, Jiaye Plaza, No. 2055, Bixin Road, Longgang District, Shenzhen

*All of our products are for R&D use only, and cannot be used in human or animal clinical use

FOLLOW US

ChemStrong

QCS R&D Center

Copyright 2006-2024 © ShenZhen ChemStrong Scientific Co., Ltd. 备案号:粤ICP备19155981号 Shenzhen Municipal Administration for Market Regulation Enterprise Identity Disclosure

CONTACT US

Service hotline: +86 0755-66853366
Marketing Department: +86 136 7004 6396 (WeChat)
Email: sales@chem-strong.com
Office address: Room 1201, Jiaye Plaza, No. 2055, Bixin Road, Longgang District, Shenzhen
*All of our products are for R&D use only, and cannot be used in human or animal clinical use

FOLLOW US

ChemStrong

QCS R&D Center

Copyright 2006-2024 © ShenZhen ChemStrong Scientific Co., Ltd. 备案号:粤ICP备19155981号 Shenzhen Municipal Administration for Market Regulation Enterprise Identity Disclosure